-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, CPvPmMvM2iHROaXsdr8yfGtA7NM0o6MhhPJK2xKstiUb/a43S++LwjWFh/pprJzA IBucmdAnT2ZK2ljxlgqWhQ== 0000910647-98-000035.txt : 19980218 0000910647-98-000035.hdr.sgml : 19980218 ACCESSION NUMBER: 0000910647-98-000035 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 19980213 SROS: NASD SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: CONCEPTUS INC CENTRAL INDEX KEY: 0000896778 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 973170244 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: SEC FILE NUMBER: 005-49585 FILM NUMBER: 98536819 BUSINESS ADDRESS: STREET 1: 1021 HOWARD AVE CITY: SAN CARLOS STATE: CA ZIP: 94070 BUSINESS PHONE: 4158027240 MAIL ADDRESS: STREET 1: 1021 HOWARD AVENUE CITY: SAN CARLOS STATE: CA ZIP: 94070 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: TARGET THERAPEUTICS INC CENTRAL INDEX KEY: 0000882238 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 953962471 STATE OF INCORPORATION: DE FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 47201 LAKEWIEW BLVD CITY: FREMONT STATE: CA ZIP: 94538 BUSINESS PHONE: 5104407700 MAIL ADDRESS: STREET 1: 47201 LAKEVIEW BLVD CITY: FREMONT STATE: CA ZIP: 94538 SC 13G 1 SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Information Statement Purusant to Rules 13d-1 and 13d-2 Under the Securities Exchange Act of 1934 (Amendment No.__)(1) Conceptus, Inc. - -------------------------------------------------------------------------------- (Name of Issuer) Common Stock, $0.003 par value per share - -------------------------------------------------------------------------------- (Title of Class of Securities) 206016107 - -------------------------------------------------------------------------------- (CUSIP Number) - ------------------- (1) The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes). CUSIP No. 206016107 13G Page 2 of 5 Pages - -------------------------------------------------------------------------------- 1 NAME OF REPORTING PERSON S.S. or I.R.S. IDENTIFICATION NO. OF ABOVE PERSON Target Therapeutics, Inc. - -------------------------------------------------------------------------------- 2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP* (a) [ ] N/A (b) [ ] - -------------------------------------------------------------------------------- 3 SEC USE ONLY - -------------------------------------------------------------------------------- 4 CITIZENSHIP OR PLACE OF ORGANIZATION The State of Delaware - -------------------------------------------------------------------------------- 5 SOLE VOTING POWER 1,418,856 NUMBER OF ---------------------------------------------------------------- SHARES 6 SHARED VOTING POWER BENEFICIALLY OWNED BY 0 EACH REPORTING ---------------------------------------------------------------- PERSON 7 SOLE DISPOSITIVE POWER WITH 1,418,856 ---------------------------------------------------------------- 8 SHARED DISPOSITIVE POWER 0 - -------------------------------------------------------------------------------- 9 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 1,418,856 - -------------------------------------------------------------------------------- 10 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES* [ ] N/A - -------------------------------------------------------------------------------- 11 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW 9 15.0% - -------------------------------------------------------------------------------- 12 TYPE OF REPORTING PERSON* CO - -------------------------------------------------------------------------------- *SEE INSTRUCTION BEFORE FILLING OUT! CUSIP No. 206016107 13G Page 3 of 5 Pages ITEM 1(a). NAME OF ISSUER: - ---------------------------- Conceptus, Inc. ITEM 1(b). ADDRESS OF ISSUER'S PRINCIPAL EXECUTIVE OFFICES: - ------------------------------------------------------------- 1021 Howard Avenue San Carlos, CA 94070 ITEM 2(a). NAME OF PERSON FILING: - ----------------------------------- Target Therapeutics, Inc. ITEM 2(b). ADDRESS OF PRINCIPAL BUSINESS OFFICE OR, IF NONE, RESIDENCE - ------------------------------------------------------------------------ 47201 Lakeview Blvd. Freemont, CA 94538 ITEM 2(c). CITIZENSHIP: - ------------------------- The State of Delaware ITEM 2(d). TITLE OF CLASS OF SECURITIES: - ------------------------------------------ Common Stock, $0.003 par value per share, (the "shares") ITEM 2(e). CUSIP NUMBER: - -------------------------- 206016107 CUSIP No. 206016107 13G Page 4 of 5 Pages ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO RULES 13D-1(B), OR 13D-2(B), CHECK WHETHER THE PERSON FILING IS A: - ---------------------------------------------------------------------- Not applicable; filed pursuant to Rule 13d-1(c) ITEM 4. OWNERSHIP: - ----------------------- (a) Amount beneficially owned: 1,418,856 shares (b) Percent of class: 15.0%(2) (c) Number of shares as to which such person has: (i) Sole Power to vote or to direct the vote: 1,418,856 shares (ii) Shared power to vote or to direct the vote: 0 shares (iii) Sole power to dispose or to direct the disposition of: 1,418,856 shares (iv) Shared power to dispose or to direct the disposition of: 0 shares ITEM 5. OWNERSHIP OF FIVE PERCENT OR LESS OF A CLASS: - ---------------------------------------------------------- Not applicable. ITEM 6. OWNERSHIP OF MORE THAN FIVE PERCENT ON BEHALF OF ANOTHER PERSON: - ----------------------------------------------------------------------------- Not applicable. ITEM 7. IDENTIFICATION AND CLASSIFICATION OF THE SUBSIDIARY WHICH ACQUIRED THE SECURITY BEING REPORTED ON BY THE PARENT HOLDING COMPANY: - -------------------------------------------------------------------------- Not applicable. ITEM 8. IDENTIFICATION AND CLASSIFICATION OF MEMBERS OF THE GROUP: - ----------------------------------------------------------------------- Not applicable. - ------------------- (2) Pursuant to Rule 13d-1(e), the Reporting Person is relying on the Form 10-Q filed by the Issuer for the quarterly period ended September 30, 1997, indicating a total of 9,476,387 shares outstanding. CUSIP No. 206016107 13G Page 5 of 5 Pages ITEM 9. NOTICE OF DISSOLUTION OF GROUP: - -------------------------------------------- Not applicable. ITEM 10. CERTIFICATION: - --------------------------- Not applicable. SIGNATURE After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct. February 12, 1998 ------------------------------------ (Date) TARGET THERAPEUTICS, INC. By: /s/ Lawrence J. Knopf ------------------------------- Name: Lawrence J. Knopf Title: Secretary -----END PRIVACY-ENHANCED MESSAGE-----